India's expert panel of Central Drugs Standard Control Organization(CDSCO) has recommended Bharat Biotech’s COVID-19 vaccine, Covaxin for second and third phase trials in children aged between two to eighteen years of age.

India's expert panel recommends Covaxin trials on 2-18 year-olds

As per the official sources, the trial for the vaccine will take place in 525 subjects at different sites, including AIIMS, Patna, AIIMS, Delhi, and Meditrina Institute of Medical Sciences, Nagpur.

Bharat Biotech’s COVAXIN gets nod for phase 2/3 trials on 2-18 years old

Bharat Biotech on Thursday announced that the price of its coronavirus vaccine Covaxin will be reduced by Rs 200 (USD 2.7) for Indian states and will be available at Rs 400 (USD 5.

Bharat Biotech reduces price of Covaxin for Indian state governments

The central government on Monday asked the Serum Institute and Bharat Biotech to lower prices of their COVID-19 vaccines amid criticism from various states, who objected to profiteering during such a major crisis.

Indian Govt asks Serum Institute, Bharat Biotech to lower price of COVID-19 vaccines: Official sources  

Bharat Biotech has fixed the price of its Covid-19 vaccine, Covaxin, at Rs 600 per dose for state governments and at Rs 1,200 per dose for private hospitals, the vaccine maker announced on Saturday.

Bharat Biotech prices Covaxin at Rs 600 for states, Rs 1,200 for pvt hospitals  

The Indian vaccine manufacturer Bharat Biotech has released its amended prices as the country aims to open up vaccination drive to all adults from 1 May.

Bharat Biotech releases Covaxin's price ahead of India's phase 3 of vaccination

Bharat BioTech on Wednesday claimed that its coronavirus vaccine Covaxin has an efficacy of 78 per cent against mild, moderate and severe cases of Covid-19, according to the Phase 3 interim analysis results.

Covaxin has an efficacy of 78% against severe Covid-19 cases: Bharat BioTech

Bharat Biotech has announced the Phase 3 clinical trial results for its Coronavirus vaccine candidate Covaxin. The company said that Covaxin demonstrated an efficacy of 81 per cent in the trials.

Bharat Biotech announces successful Phase-3 trial results of Covaxin

Participants received a vaccine or placebo in a 1:1 ratio, which showed that the vaccine candidate was well tolerated, said the company

Covaxin showed 81% efficacy against UK variant

Indian firm Bharat Biotech's homegrown Covid vaccine has shown an interim efficacy of 81 per cent in late-stage clinical trials, the company has said. The trials involved 25,800 subjects in partnership with the Indian Council of Medical Research, the Hyderabad-based company said in a statement on Wednesday.

Bharat Biotech's Covaxin found 81% efficient in Phase 3 trials

According to reports, Chinese hacking groups are targeting Indian vaccine makers Serum Institute of India (SII) and Bharat Biotech. Both SII and Bharat Biotech are involved in producing the COVID-19 vaccine.

Report: Hackers target Indian vaccine makers SII, Bharat Biotech

Brazil's health ministry on Thursday signed a deal with India's Bharat Biotech to purchase 20 million doses of Covaxin, a coronavirus vaccine. The news came a day before Brazil marks one year since the first case of Covid-19 was confirmed in the country after a Sao Paulo businessman returning from a trip to Italy tested positive.

Brazil signs deal with India's Bharat Biotech for 20 million Covid-19 vaccine doses

India's exports of the COVID-19 vaccine stood at around Rs 338 crore till February 8, Commerce and Industry Minister Piyush Goyal said in the Rajya Sabha on Friday.

India has exported vaccines worth Rs 338 crore: Government declares in Parliament

According to a new study, India's homegrown jab Covaxin is likely to be effective against the UK variant of the Coronavirus. Covaxin is developed by Bharat Biotech, it has been approved for emergency use by India's drug regulators.

Study: Covaxin developed by Indian Pharma firm Bharat Biotech neutralizes UK variant

Britain`s GSK will shift production of the world`s first effective malaria vaccine to Indian COVID-19 vaccine developer Bharat Biotech, as part of global efforts to battle the deadly fever, the drugmakers said on Wednesday.

GSK to move malaria vaccine production to India's Bharat Biotech

Indian drugmaker Bharat Biotech's coronavirus vaccine, which has been authorized for use in the country, proved safe and produced an immune response in a small group of adults aged 18 to 55, according to a study published in The Lancet medical journal.

Bharat Biotech's COVID-19 shot safe, produced immune response in early human trial: Study

India's Bharat Biotech submitted on Thursday an application for the emergency use of its COVID-19 vaccines in the Philippines, Food and Drug Administration chief Rolando Enrique Domingo said.

India's Bharat Biotech seeks emergency use approval for vaccine in Philippines

There will be a gap of 28 days between two doses of COVID-19 vaccine and its effectiveness will begin 14 days after the second dose, the Health Ministry said on Tuesday.

Gap of 28 days between two Covid vaccine doses, effectiveness to begin after 14 days: Government

After Delhi, the first consignment of India's Serum Insitute's coronavirus vaccine arrived in Hyderabad airport. Also Read: First flight of coronavirus vaccine Covishield flown to Delhi "The first consignment of the vaccine will be going to 11 destinations outside the state by this evening," Hyderbad airport CEO Pradeep Panicker said.

Coronavirus vaccine arrives in Hyderabad; Gujarat, Tamil Nadu set to receive consignment

Various global leaders such as tech genius Bill Gates and the Director-General of the World Health Organization Tedros Adhanom Ghebreyesus have congratulated India for its quick and decisive actions regarding the coronavirus vaccine.

Bill Gates and other world leaders applaud India for quick vaccine production

India's Central Drugs Standard Control Organization (CDSCO) expert panel on Saturday recommended approving restricted emergency use of Bharat Biotech's indigenous COVID vaccine Covaxin in India, said officials.

Expert panel recommends India's indigenously developed Covid-19 vaccine Covaxin for restricted emergency use

A day after India's drug regulator approved COVAXIN for emergency use, various private clinics in Brazil are seeking Bharat Biotech's vaccine to fight against the increasing coronavirus tally.

Brazil's private clinics seek India's COVAXIN vaccine

Indian Government to approve their vaccine called COVAXIN by Bharat Biotech, this could be a game changer in fight against covid pandemic. The vaccine is currently on Phase 3rd trial.

Indian vaccine could be the game changer in fight against COVID-19

VG Somani, the Drug Controller General of India said on Monday that Covishield and Covaxin are ''safe and provide a robust immune response.'' India's drugs regulator has given final emergency-use approval for two coronavirus vaccines, Serum Institute of India's Covishield, developed by Oxford University and pharma major AstraZeneca, and Bharat Biotech's Covaxin.

Covishield, Covaxin are safe and provide robust immune response, says Drug Controller General of India VG Somani

bharat-biotech

Bharat Biotech, News on Bharat Biotech, stories on Bharat Biotech, articles on Bharat Biotech, Bharat Biotech stories at Wion, Bharat Biotech news, Bharat Biotech latest news

bharat biotech